Deadlines for grant rounds

Alzheimer's Society is open to funding research across all areas of dementia that is considered the highest quality and of greatest relevance to people affected by dementia. 

The research programme is organised into two streams, biomedical research and care, services and public health research that cover the full scope of dementia research.

We are committed to increasing our investment in care research that will help people living with dementia today.

Open calls

Round Opening Date Closing date
Alzheimer's Society and ADDF Drug Discovery call Ongoing 10 August 2018 (Letter of Intent by 13 July 2018)
Alzheimer Nederland Knowledge Exchange Fellowships  Open  Midday 1 October 2018
Clinical training partnerships Open  Midday 28 September 2018
Project grants Open  Midday 28 September 2018
Clinician and healthcare professional fellowships Open  Midday 28 September 2018
Junior fellowships Open  Midday 28 September 2018
Senior fellowships Open  Midday 28 September 2018
PhD studentships Open  Midday 28 September 2018
Dissemination grants Open Midday 31 August 2018

Highlight notice

We welcome research proposals across cause, cure, care and prevention of all forms of dementia through our biomedical and care, services and public health funding streams.

However, we wish to highlight several areas where we would welcome more applications to our regular grant rounds in the hope of funding in these areas.

These areas remain open to our six-monthly call deadlines.

Real-world utility of biomarkers:  There are a number of biological markers including amyloid-PET and other neuroimaging approaches, CSF analysis; genotyping, advanced neuropsychology and others that may add value and guide clinical decision making.

We welcome research proposals that seek to address facilitators and barriers to their implementation in real-world settings, as well as provide information about to which patient groups these tests should be offered and when, or about their utility, efficacy and impact on diagnosis, cost, or social and ethical implications of being offered to patients.

Drug repurposing: We've supported a programme of drug discovery particularly focused on drugs repurposing since 2014. We would welcome both preclinical and clinical applications that include the identification and testing of repurposed drug possibilities.

In addition we fund clinical trials of drug candidates with our US partner the Alzheimer’s Drug Discovery Foundation (ADDF) through cofounding in their PACT programme.

Our grant application process

Visit our applications page to learn about our funding process and how you can submit a high quality research application. 

Learn more

Need help applying for our project, PhD or fellowship grants?

We are hosting a webinar that will guide potential applicants through our applications process and provide tips for developing and submitting an application. It will complement information included in our applicant guidance. 

Webinar date

Wednesday 29th August 2018 -12:00-13:00

To participate, please email [email protected] to register your interest in attending.

Resubmission policy

Applicants may resubmit a revised application, for the same project, after rejection by the Grants Advisory Board, but only once. A resubmitted application can only be submitted after at least 12 months have passed since the original application was made. In other words, not to subsequent closing deadlines which are six months apart.

The Grants Advisory Board will expect the project to be sufficiently revised to take into account any reviewer feedback and further developments in the research field.

Sign up to Research Funding Updates

We encourage you to sign up to our Research Funding Updates. Your information will only be used by the Research team to keep you informed about new opportunities and dementia research funding.

Think this page could be useful to someone? Share it:
Categories

Further reading